What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading ->
A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit. Continue reading ->
On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam. Continue reading ->
Geneva, 21 Nov (TWN) - A discussion document prepared by the Secretariat of the World Health Organization (WHO) proposes criteria to justify interventions with respect to medicines in transit. This document is prepared for the 6th meeting of the Member State Mechanism (MSM) to be held from 28 November to 1 December at the WHO headquarters in Geneva, writes Third World Network. Continue reading ->
NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading ->
World Health Organization Director General Tedros Adhanom Ghebreyesus (Tedros) admonished member states at the close of this week’s special session of the WHO Executive Board charged with examining the agency’s draft work programme for 2019-2023. A trust deficit among member states leads to the multiplication of national statements, impeding efficiency, he said. Meanwhile, a number of countries called for affordable and accessible medicines, and help to manufacture generic medicines locally, while the United States pushed the role of the private sector. Continue reading ->